Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

被引：0
|
作者：
Ruth M. de Tute
Gordon Cook
David A. Cairns
Julia M. Brown
Jamie Cavenagh
A. John Ashcroft
John A. Snowden
Kwee Yong
Eleni Tholouli
Matthew Jenner
Anna Hockaday
Mark T. Drayson
Treen C. M. Morris
Andy C. Rawstron
Roger G. Owen
机构：
[1] Leeds Teaching Hospitals Trust,Haematological Malignancy Diagnostic Service
[2] University of Leeds,Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research
[3] Barts & The London NHS Trust,Department of Haematology
[4] Mid-Yorks NHS Trust,Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust & Department of Endocrinology & Metabolism
[5] University of Sheffield,Department of Haematology
[6] University College London,Department of Clinical Haematology, Manchester Royal Infirmary
[7] Manchester Foundation Trust,undefined
[8] University Hospital Southampton NHS Foundation Trust,undefined
[9] Institute of Immunology and Immunotherapy University of Birmingham,undefined
[10] College of Myeloma,undefined
来源：
Bone Marrow Transplantation | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 434
页数：3
相关论文
共 50 条
  • [1] Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
    de Tute, Ruth M.
    Cook, Gordon
    Cairns, David A.
    Brown, Julia M.
    Cavenagh, Jamie
    Ashcroft, A. John
    Snowden, John A.
    Yong, Kwee
    Tholouli, Eleni
    Jenner, Matthew
    Hockaday, Anna
    Drayson, Mark T.
    Morris, Treen C. M.
    Rawstron, Andy C.
    Owen, Roger G.
    BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 431 - 434
  • [2] SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA
    Zannetti, B. A.
    Pezzi, A.
    Gamberi, B.
    Zamagni, E.
    Tosi, P.
    Rocchi, S.
    Cellini, C.
    Tacchetti, P.
    Ronconi, S.
    Pantani, L.
    Mancuso, K.
    Martello, M.
    Santacroce, B.
    Cavo, M.
    HAEMATOLOGICA, 2015, 100 : 510 - 510
  • [3] SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA
    Zannetti, B. A.
    Pezzi, A.
    Gamberi, B.
    Zamagni, E.
    Tosi, P.
    Rocchi, S.
    Cellini, C.
    Tacchetti, P.
    Ronconi, S.
    Pantani, L.
    Mancuso, K.
    Rizzello, I.
    Martello, M.
    Testoni, N.
    Cavo, M.
    HAEMATOLOGICA, 2015, 100 : 32 - 32
  • [4] Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial
    de Tute, Ruth Mary
    Rawstron, Andy C.
    Cairns, David A.
    Pawlyn, Charlotte
    Davies, Faith E.
    Collett, Corinne
    Kaiser, Martin F.
    Jones, John R.
    Waterhouse, Anna
    Striha, Alina
    Cook, Gordon
    Jenner, Matthew W.
    Russell, Nigel H.
    Drayson, Mark T.
    Gregory, Walter M.
    Jackson, Graham H.
    Morgan, Gareth J.
    Owen, Roger G.
    BLOOD, 2016, 128 (22)
  • [5] Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
    Boncompagni, Riccardo
    Staderini, Michela
    Nozzoli, Chiara
    Antonioli, Elisabetta
    Caporale, Roberto
    Peruzzi, Benedetta
    Cutini, Ilaria
    Gozzini, Antonella
    Serena, Mariotti
    Guidi, Stefano
    Jance, Blerina
    Accogli, Barbara
    Francesco, Annunziato
    Bosi, Alberto
    Saccardi, Riccardo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E172 - E172
  • [6] The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial
    Ashcroft, John
    de Tute, Ruth M.
    Cairns, David A.
    Fletcher, Marie
    Owen, Roger G.
    Rawstron, Andy
    O'Connor, Sheila J. M.
    Williams, Cathy D.
    Snowden, John A.
    Cavenagh, J. D.
    Parrish, Christopher
    Morris, Treen
    Brown, Julia M. B.
    Cook, Gordon
    BLOOD, 2013, 122 (21)
  • [7] Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
    Kaedbey, Rayan
    Hay, Kevin
    Masih-Khan, Esther
    Kardjadj, Moustafa
    McCurdy, Arleigh
    Chu, Michael P.
    Jimenez-Zepeda, Victor H.
    Leblanc, Richard
    Song, Kevin
    Mian, Hira S.
    Louzada, Martha L.
    Sebag, Michael
    Reiman, Anthony
    White, Darrell J.
    Venner, Christopher P.
    Stakiw, Julie
    Kotb, Rami
    Aslam, Muhammad
    Bergstrom, Debra
    Gul, Engin
    Reece, Donna E.
    BLOOD, 2022, 140 : 10002 - 10004
  • [8] Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma
    Braunstein, Marc
    Niesvizky, Ruben
    SEMINARS IN ONCOLOGY, 2016, 43 (06) : 709 - 711
  • [9] Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma
    Gupta, Ritu
    Kumar, Lalit
    Dahiya, Meetu
    Mathur, Nitin
    Harish, P.
    Sharma, Atul
    Sharma, Om Dutt
    Shekhar, Varun
    LEUKEMIA & LYMPHOMA, 2017, 58 (05) : 1234 - 1237
  • [10] MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) BEFORE AND AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
    Galtseva, I.
    Mendeleeva, L.
    Pokrovskaya, O.
    Kastrikina, I.
    Urnova, E.
    Kuzmina, L.
    Parovichnikova, E.
    Savchenko, V.
    HAEMATOLOGICA, 2014, 99 : 647 - 647
12345